Brent  Pfeiffenberger net worth and biography

Brent Pfeiffenberger Biography and Net Worth

Brent Pfeiffenberger is President and Chief Executive Officer at Century Therapeutics and the Chair of its Board of Directors. Prior to joining Century, Dr. Pfeiffenberger served as Chief Operating Officer of Neogene Therapeutics. He played a central role in driving Neogene’s evolution from a preclinical company to a global, clinical-stage organization with multiple assets, ultimately culminating in its acquisition by AstraZeneca in 2023. Prior to Neogene, Dr. Pfeiffenberger spent nearly two decades in leadership roles of increasing responsibility at Bristol Myers Squibb, most recently as Senior Vice President, Head of U.S. Oncology, where he oversaw business operations for the multi-billion dollar franchise. Earlier, he held several critical global leadership positions where he built, led, and expanded commercial and business operations, including as Co-Lead, Head of Worldwide Commercial Oncology, where he closely partnered with the Research and Development team on the creation and delivery of global development strategies for a large-scale oncology program. Dr. Pfeiffenberger received his PharmD from Duquesne University and his MBA from the Wharton School of Business at the University of Pennsylvania.

What is Brent Pfeiffenberger's net worth?

The estimated net worth of Brent Pfeiffenberger is at least $7.56 million as of December 12th, 2025. Mr. Pfeiffenberger owns 3,322,990 shares of Century Therapeutics stock worth more than $7,559,802 as of April 24th. This net worth approximation does not reflect any other investments that Mr. Pfeiffenberger may own. Learn More about Brent Pfeiffenberger's net worth.

How do I contact Brent Pfeiffenberger?

The corporate mailing address for Mr. Pfeiffenberger and other Century Therapeutics executives is , , . Century Therapeutics can also be reached via phone at 267-817-5790 and via email at [email protected]. Learn More on Brent Pfeiffenberger's contact information.

Has Brent Pfeiffenberger been buying or selling shares of Century Therapeutics?

Brent Pfeiffenberger has not been actively trading shares of Century Therapeutics over the course of the past ninety days. Most recently, on Friday, December 12th, Brent Pfeiffenberger bought 52,000 shares of Century Therapeutics stock. The stock was acquired at an average cost of $0.58 per share, with a total value of $30,160.00. Following the completion of the transaction, the chief executive officer now directly owns 3,322,990 shares of the company's stock, valued at $1,927,334.20. Learn More on Brent Pfeiffenberger's trading history.

Who are Century Therapeutics' active insiders?

Century Therapeutics' insider roster includes Eli Casdin (Director), Osvaldo Flores (Pres), Brent Pfeiffenberger (CEO), and Gregory Russotti (Insider). Learn More on Century Therapeutics' active insiders.

Are insiders buying or selling shares of Century Therapeutics?

During the last year, Century Therapeutics insiders bought shares 3 times. They purchased a total of 145,060 shares worth more than $97,011.00. During the last year, insiders at the sold shares 18 times. They sold a total of 92,974 shares worth more than $80,629.43. The most recent insider tranaction occured on March, 12th when SVP Douglas Carr sold 7,043 shares worth more than $17,959.65. Insiders at Century Therapeutics own 4.4% of the company. Learn More about insider trades at Century Therapeutics.

Information on this page was last updated on 3/12/2026.

Brent Pfeiffenberger Insider Trading History at Century Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2025Buy52,000$0.58$30,160.003,322,990View SEC Filing Icon  
11/19/2025Buy35,000$0.50$17,500.003,271,453View SEC Filing Icon  
11/17/2025Sell32,456$0.45$14,605.203,236,453View SEC Filing Icon  
11/17/2025Sell32,456$0.45$14,605.203,236,453View SEC Filing Icon  
9/8/2025Sell488$0.50$244.003,268,909View SEC Filing Icon  
6/9/2025Sell475$0.62$294.501,681,783View SEC Filing Icon  
3/10/2025Sell2,235$0.61$1,363.351,190,310View SEC Filing Icon  
See Full Table

Brent Pfeiffenberger Buying and Selling Activity at Century Therapeutics

This chart shows Brent Pfeiffenberger's buying and selling at Century Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Century Therapeutics Company Overview

Century Therapeutics logo
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $2.28
Low: $2.20
High: $2.30

50 Day Range

MA: $2.29
Low: $1.75
High: $2.94

2 Week Range

Now: $2.28
Low: $0.44
High: $3.04

Volume

507,459 shs

Average Volume

1,729,199 shs

Market Capitalization

$409.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66